stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Free cash flow margin
Sarepta Therapeutics, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 9.02%, up 23.4 percentage points from fiscal 2025 (−14.3%). Over the past ten years it has ranged from −12,314.3% (fiscal 2015) to 24.7% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −14.3% | 4.21 |
| FY2024 | −18.6% | 20.57 |
| FY2023 | −39.1% | (0.79) |
| FY2022 | −38.3% | 16.09 |
| FY2021 | −54.4% | (79.11) |
| FY2020 | 24.7% | 160.21 |
| FY2019 | −135.5% | 13.90 |
| FY2018 | −149.4% | (66.48) |
| FY2017 | −82.9% | 4,578.30 |
| FY2016 | −4,661.2% | 7,653.05 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 32.7% |
| SRPT Sarepta Therapeutics, Inc. | 9.02% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MAZE Maze Therapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| TRVI Trevi Therapeutics, Inc. compare | 0.00% |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −5.89% |
| VIR Vir Biotechnology, Inc. compare | −46.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue